Y Intercept Hong Kong Ltd Sells 12,943 Shares of Insulet Co. (NASDAQ:PODD)

Y Intercept Hong Kong Ltd cut its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 75.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,272 shares of the medical instruments supplier's stock after selling 12,943 shares during the period. Y Intercept Hong Kong Ltd's holdings in Insulet were worth $994,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PODD. Sequoia Financial Advisors LLC lifted its position in shares of Insulet by 8.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,089 shares of the medical instruments supplier's stock worth $422,000 after buying an additional 157 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Insulet by 36.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 2,351 shares of the medical instruments supplier's stock valued at $474,000 after buying an additional 625 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Insulet by 38.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier's stock worth $36,202,000 after purchasing an additional 50,101 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Insulet by 90.1% in the second quarter. Nisa Investment Advisors LLC now owns 3,797 shares of the medical instruments supplier's stock valued at $766,000 after buying an additional 1,800 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in shares of Insulet during the second quarter valued at $106,000.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PODD. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price for the company. Morgan Stanley increased their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. Wells Fargo & Company upped their price objective on shares of Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday. Citigroup upped their price target on Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $267.44.

Insider Buying and Selling at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.47% of the company's stock.

Insulet Trading Down 0.9 %

Shares of PODD stock traded down $2.39 on Friday, reaching $269.34. 571,633 shares of the stock were exchanged, compared to its average volume of 762,207. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a one year low of $160.19 and a one year high of $279.77. The stock has a market cap of $18.89 billion, a PE ratio of 46.53, a P/E/G ratio of 4.18 and a beta of 1.21. The stock has a 50 day moving average price of $250.58 and a 200 day moving average price of $219.40.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.